Irampanel Boehringer Ingelheim.
The oxazole derivative, irampanel, a non-competitive AMPA receptor antagonist, is under development by Boehringer Ingelheim for the potential treatment of stroke [329079]. Phase I/IIa trials for stroke had been initiated by July 2000 [374144]. Phase II trials were ongoing in April 2001 [407163]; in April 2002, however, the drug did not appear on the company's research and development pipeline [446554], and a company spokesperson declined to confirm its current status [450591]. The compound was also originally under investigation for other neurological disorders, including epilepsy and pain [329079], although by October 1999, development was only ongoing for stroke [346080].
Feigin
Valery
V
University of Auckland, Department of Medicine, New Zealand. v.feigin@ctru.auckland.ac.nz
D000818:Animals; D017321:Clinical Trials, Phase I as Topic; D004195:Disease Models, Animal; D006801:Humans; D010069:Oxadiazoles / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D018091:Receptors, AMPA / Q000037:antagonists & inhibitors*; D020521:Stroke / Q000188:drug therapy*
D010069:Oxadiazoles; D018091:Receptors, AMPA; C119322:irampanel